Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
|Videos|August 17, 2016
The Evolving Field of Immuno-Oncology
Author(s)Madhav Dhodapkar, MBBS
Madhav Dhodapkar, MBBS, clinical research program leader, Hematology Program, Yale Cancer Center, discusses the evolving field of immuno-oncology and the significant benefits it stands to have for patients.
Advertisement
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival with standard of care in glioblastoma but showed benefit in patients aged 65 and below.
Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.
Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.
Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer
2
Hormone Receptor Status, HER2DX Score Predict Response to Neoadjuvant THP
3
Adding Quality of Life to Treatment Goals in Immune Thrombocytopenia
4
Prostate and Rare Cancer Agents Nab FDA Fast Track Status
5